This site is intended for US healthcare professionals only

SEE LESS Recurring INFLAMMATION
SEE MORE CONTINUOUS CALM™
GET YUTIQ
HELP APPROPRIATE UVEITIS PATIENTS
SEE LESS RECURRENCE
SEE MORE VISION STABILITY
GET YUTIQ
SEE LESS Obstacles To Treatment
SEE MORE Access For Patients
GET YUTIQ

What Makes YUTIQ Different?

YUTIQ® is the only uveitis treatment that provides consistent, continuous drug delivery for up to 36 months.1 YUTIQ helps prevent recurrence of uveitic inflammation and edema, providing the calm that comes with a quiet eye.2, 3

This close-up view shows the small size of the YUTIQ implant compared to a dime.

Uveitis specialists & retina specialists trust YUTIQ

Dr. Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center in San Antonio, Texas, speaks about the ideal patient, use of YUTIQ, and patient follow-up. He performs a YUTIQ injection on an actual patient in his office.

Retina specialist Dr. Eichenbaum discusses the ideal YUTIQ patient, the use of YUTIQ, and follow-up care.

Helping Your Patients Access YUTIQ

Comprehensive reimbursement & access services for your office & your patients

The AccessPlus Program offers streamlined patient reimbursement support services and is easily integrated into your patient processing system. AccessPlus supports your patients with comprehensive services built around your practice needs.

Download enrollment form

We are available to answer any questions about YUTIQ. Please complete the following form to contact us today.

Join our
Physician Directory!

Fill out a quick form to help potential
YUTIQ patients find you.
Link to Healthcare Professionals Site
The information contained on this site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.

References

  1. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-006
  2. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-001
  3. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-003
  4. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.
  5. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-002.

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023
  2. Thorne JE, Suhler E, Skup M, et al. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol. 2016;134(11):1237-1245. 2016;134:1237-1245.
  3. Chorich LJ III, et a;. Diagnosis and Treatment of Uveitis. 2013.

Study Design

  1. Study design: The efficacy of YUTIQ was assessed in 2 randomized, multicenter, sham-controlled, double-masked, phase 3 studies in adult patients [N=282] with noninfectious uveitis affecting the posterior segment of the eye. The primary endpoint in both studies was the proportion of patients who experienced recurrence of uveitis in the study eye within 6 months of follow-up; recurrence was also assessed at 12 months. Recurrence was defined as either deterioration in visual acuity, vitreous haze attributable to noninfectious uveitis, or the use of confounding medications.1

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.
  2. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-007
  3. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-008